Kidney disease biobank aims to unlock new treatments

NCT ID NCT04174066

Knowledge-focused Sponsor: Centre Hospitalier Universitaire de Nice Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is collecting blood, urine, and kidney tissue samples from 144 children and adults with a kidney condition called nephrotic syndrome. The goal is to build a large database and sample collection to study how the immune system and kidney cells interact. Researchers hope this will help find new treatment targets and reduce reliance on steroids and other drugs with many side effects.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to: If successful, this could identify new drug targets for nephrotic syndrome, potentially leading to more effective treatments with fewer side effects.
What could go wrong: This is an observational biobank study, not a treatment trial. It may not directly lead to new therapies, and results may take years to translate into clinical use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 144 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2020

Expected to finish

May 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

patient with Idiopathic Nephrotic Syndrome

Ages

12 months and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * First episode of idiopathic nephrotic syndrome in a child aged 12 months to 18 years with a weight \> 10 kg and biologically defined as proteinuria \> 0.20 g / mmol creatinuria and hypoalbuminemia \<25 g / mmol * First episode of NIS defined in adults as albumin level \<30 g / L and a urinary protein/creatinine ratio (UPCR) ≥ 300 mg / mmol systematically associated with the performance of a renal anatomopathological examination and characterized by the absence of identifiable lesions by light microscopy (SNLGM) or the presence of HSF lesions. * For adults: signed informed consent to participate in the study * For children: patients will be informed and a written informed consent form will be signed by both parents of the children at inclusion * Patients affiliated to the French health system Exclusion Criteria: * Patients who have previously received corticosteroids and/or immunosuppressants * Patients with reduced CH50 and/or low C3 and/or low C4 and/or low C4 (in some cases increased sC5b9 and/or presence of a C3 nephritic Factor; an anti-C3b...) * SNLGM resulting from a secondary process (lymphoid hematopathies or neoplasia) or occurring following the administration of a treatment known to be associated with an SNLGM (lithium, interferon, non-steroidal anti-inflammatory drugs) * Non-primary FHH (absence of Nephrotic Syndrome, etiological assessment revealing FHH secondary to an identified cause (genetic or not), no introduction of corticosteroids or immunosuppressants as first-line treatment) * Positive serological screening test for HIV, hepatitis B or C * Positive immunological tests for antinuclear and anti-DNA antibodies or anti-PLA2R1 and anti-THSD7A * Patient under guardianship or curatorship

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Idiopathic nephrotic syndrome are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

idiopathic nephrotic syndrome lipoid nephrosis nephrotic syndrome primary focal segmental glomerulosclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Nephrotic syndrome

How to take part

Only the study team decides who joins. These are the ways to reach them.

The places running it

2 sites. The list below names each one and where it is.
The official record

ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

Open the record ↗
A doctor treating you

A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Kidney disease biobank aims to unlock new treatments

What the study statuses mean